Background: Measuring fasting C-peptide (FCP) and antibodies against Glutamic acid decarboxylase (GADA) and Islet cell antibodies (ICA) are not so commonly explored in children and young adults. Objectives: To assess the levels of FCP, GADA and ICA in subjects below the age of 25 years with DM and compare their levels to differentiate between Autoimmune and Non-Autoimmune Type 1 DM. Methodology: Blood samples of 93 subjects diagnosed with DM, reporting to the tertiary care hospital, were analysed for ICA, GADA and FCP. Receiver operating characteristics (ROC) curves were analysed to check the ability of autoimmune markers, BMI and C-peptide to differentiate between Autoimmune (Ai) and Non-Autoimmune (NonAi) diabetes. Results: 30/93 (32.2%) were positive for anti-GAD ab and/or ICA and categorised as Autoimmune (Ai), the most common antibody being, anti-GAD ab (80%) in them. The level of FCP among Ai compared to NonAi, was significantly low (p < 0.001). The combined effect of Age and BMI on the level of FCP was lesser in autoimmune diabetes. Receiver Operating Characteristic Curve ROC analysis demonstrated the advantage of raised GAD ab (>20.75 nmol/l) as a very dependable test for diagnosing Ai, Type 1 DM, in children and young adults. Its sensitivity and specificity are in the range of 86.2% and 96.8% respectively. Low level of C-peptide (<0.36 nmol/l) is a fair indicator for diagnosing Ai diabetes in the same population unlike BMI. Conclusion: This study revealed predominant positivity for anti-GAD ab (80%) among Ai+ patients. ROC analysis shows GADA above 20.75 nmol/l and Fasting C-peptide < 0.36 nmol/l as a good indicator for diagnosing Ai in children and young adults.
Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycaemia consequent to defects in Insulin secretion, action or both. The etiopathogenic mechanisms behind developing chronic hyperglycaemia are not common to all [
In India, prevalence of T1DM is lesser than in Europe and North America. Reviews have shown that there are three new cases of T1DM/100,000 children of 0 - 14 years [
Type 1 DM is mostly due to autoimmune destruction of Islet β cells at early stage of life [
Islet β cells activity and reserve for insulin can be assessed by analysing circulating levels of connecting peptide (C-Peptide) in blood. C-peptide is the part of proinsulin which is cleaved prior to co-secretion with insulin from pancreatic beta cells. It being metabolically inert, is widely used to measure pancreatic β cell function [
The aim of this study was to assess the levels of C-peptide, and their relations to age and levels of circulating antibodies against β cells (anti-GAD Ab and Islet cell Ab), in children and young adults with newly diagnosed DM and also to explore the usefulness of C-peptide levels, BMI and age in classification of diabetes at diagnosis in the children and young patients.
Our study was cross-sectional study conducted in the Post Graduate Department of Medicine of S.C.B. Medical College and Hospital, Odisha between January 2017 to January 2019.
In total, 93 consecutive newly diagnosed patients with DM as per WHO criteria in different wards and clinics with age at the onset of diabetes between 0 to 25 years attending, admitted and under care of consultants attached to Department of Medicine, Endocrinology and Paediatrics were enrolled for the study. The study was conducted in a specialised centre for the purpose in the Department of Medicine. The population was ethnically homogeneous with majority coming from the adjacent districts of Cuttack. The study was approved by the Ethics Committee of the Institution.
DM was diagnosed according to World Health Organisation (WHO) criteria [
Blood samples were collected at the time of diagnosis. Blood glucose was done by glucose oxidase method in venous blood. Glycosylated Hemoglobin (Hb A1c) estimation was done by ion exchange chromatography method. All the selected patients were evaluated for the presence of Islet cell antibody (ICA), Glutamic acid decarboxylase antibody (anti-GADab) and fasting C-peptide (FCP). C-peptide was analysed by chemiluminescence by COBAS E411, manufactured by Roche Diagnostics, Germany and marketed in India by Roche Diagnostics Private Limited and kits manufactured by Roche Diagnostics, Germany.
ICA levels were analysed by ESILA, Instrument—BIO-RAD IMARK, manufactured in Japan and marketed in India by Immunoshop Private Limited. Kits were manufactured by AESKU Diagnostics, Germany with a detection limit of 9 JDF-U, sensitivity 100% and specificity 88%; <30.00 IU/ml. Ant-GAD ab levels were analysed with radioimmunoprecipitation in the same machine as ICA. Both analyses were standardised according to the Diabetes Antibody Standardization Program.
The term autoimmune diabetes (Ab+) was used if subjects were positive to at least one of the antibodies to islet cells and/or glutamic acid decarboxylase. Those negative for both antibodies were designated nonautoimmune (Ab−).
Height and weight of young diabetes patients were measured by a nurse in the department. BMI (kg/m2) were calculated within each annual age category, and percentiles calculated according to Indian Academy of Paediatrics [
Family history of diabetes in grandparents, parents and siblings were taken in all subjects.
The relationship between FCP and blood glucose level at the time of sampling for FCP was investigated.
Descriptive statistics are reported in 5-year-age groups and five BMI groups. Differences between groups were explored by ANOVA/Kruskal Wallis Test wherever applicable, when appropriate with post hoc Bonferroni correction. The quantitative non-parametric data and parametric data were analysed using Mann–Whitney U and Student’s t-test for independent samples respectively. Receiver operating characteristics (ROC) curves were analysed to check the ability of age, BMI and C-peptide to differentiate between auto-antibody positive (Ab+) and negative (Ab−) diabetes. The data was analysed by SPSS version 25. All tests were two tailed, and a significance level of 0.05 was considered significant.
The study has enrolled 93 patients (32.2% male; 67.8% female). There was no significant gender difference in the proportional distribution of diabetes categories. Out of the 93 patients, 30 (32.2%) were positive for antibodies and nomenclature as Autoimmune (Ai+) and the rest as Non-Autoimmune (Non-Ai) respectively was done. The basic characteristics of the two groups are presented in
The markers of autoimmune destruction of islet β cells i.e. presence of anti-GAD ab and ICA and levels in terms of median and Q1Q3 were significantly higher in Ai+ group [GADA: 95.8 (44.6 - 215.5); ICA: 9.5 (6.6 - 27.2)] as compared to NonAi group [GADA: 5.6 (2.4 - 8.13); ICA: 7.8 (4.6 - 10.8)] (P values 0.01, <0.001 respectively).
The median age of Ai patients was significantly lower as compared to NonAi. Among the Non-Ai patients, 13/53 (20.63%) had family history of Diabetes, which was significantly higher (p < 0.001) than Ai patients 1/30 (3.3%).
| Characteristics | Autoimmune (n = 30) (Mean ± SD) | Non-autoimmune (63) (Mean ± SD) | P value# |
|---|---|---|---|
| Age in months Median (Q1 - Q3) | 9.4 ± 6.2 9.0 (0.66 - 25) | 15.7 ± 6.8 16 (0.16 - 25) | <0.001* |
| BMI | 16.04 ± 5.1 | 17.7 ± 5.8 | 0.21 |
| FBG | 242.4 ± 96.2 | 233 ± 107.9 | 0.68 |
| PPBG | 327.07 ± 128.5 | 316 ± 145.8 | 0.73 |
| HbA1C | 9.4 ± 2.1 | 9.7 ± 3.7 | 0.84 |
| C peptide (IU/ml) Median (Q1 - Q3) | 0.36 ± 0.35 0.24(0.1 - 0.49) | 1.2 ± 5.2 0.83 (0.4 - 1.7) | <0.001 |
| Islet cell Ab (IU/ml) Median (Q1 - Q3) | 49.2 ± 97.6 9.5(6.6 - 27.2) | 8.3 ± 5.2 7.8 (4.6 - 10.8) | 0.009* |
| GADA (IU/ml) Median (Q1 - Q3) | 211.72 ± 400.41 95.8 (44.6 - 215.5) | 6.07 ± 4.7 5.6 (2.4 - 8.13) | <0.001* |
| Family history Positive Negative | 1 (3.3) 29 (96.7) | 13 (20.63) 50 (79.37) | 0.029** |
| Gender Males Females | 16 (53.3) 14 (46.7) | 31 (49.2) 32 (50.8) | (0.71) |
#Independent Sample T test, *Mann-Whitney U test, **ξ2 (Chi square) test.
The other parameters like BMI, FBG, PPBG, HbA1C and duration of diabetes in months were comparable.
The mean FCP was 0.94 ± 1.19 (range-0.01 - 8.28) nmol/l. Mean FCP was significantly lower in the newly diagnosed with Ai diabetes than that in the NonAi group (
Results showed that 24/30 (80%) were positive for anti-GADA ab, 4/30 (13.3%) for ICA and only 2/30 (6.6%) were positive for both the antibodies. The mean FCP in only anti-GAD ab positive subjects, 0.33 range 0.01 - 1.00, was lower than that in the NonAi, 1.21, range 0.01 - 8.28, where the difference was significant. There were no significant differences in the levels of C-peptide between any of the Ab+ groups.
The level of FCP increased significantly with age at diagnosis in both Ai and Non-Ai new diabetes cases (both P < 0.001). For every 1-year increase in age in the newly diagnosed, FCP was 0.05 nmol/l higher in Ai and 0.02 nmol/l higher in NonAi cases. However, the positive strong correlation between FCP and age was apparent upto 0 - 10 years in Ai+ group, and 16 - 25 age group in Ai- group (
| C-peptide | BMI | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age (Years) | N | Autoimmune | N | Non-Autoimmune | P, Ai vs Non-Ai | n | Autoimmune | n | Non-Autoimmune | P, Ai vs Non-Ai |
| 0 - 5 | 08 | 0.25 ± 0.19 0.25 (0.01 - 0.58) | 04 | 0.23 ± 0.11 0.23 (0.1 - 0.36) | 1 | 04 | 13.55 ± 1.42 13.6 (12 - 15) | 02 | 14.6 ± 0.56 14.6 (14 - 15) | 0.393 |
| 6 - 10 | 13 | 0.30 ± 0.29 0.21 (0.01 - 0.58) | 12 | 0.56 ± 0.55 0.42 (0.01 - 1.95) | 0.347 | 13 | 14.3 ± 3.0 14.4 (9 - 20) | 12 | 12.63 ± 2.1 12.5 (9 - 17) | 0.113 |
| 11 - 15 | 05 | 0.25 ± 0.34 0.12 (0.01 - 0.87) | 15 | 1.69 ± 2.01 1.02 (0.42 - 8.28) | 0.002 | 05 | 21.1 ± 8.8 16.8 (13 - 33) | 15 | 17.01 ± 5.36 14.3 (12.32) | 0.225 |
| 16 - 20 | 01 | 0.25 | 12 | 1.23 ± 0.91 0.91 (0.32 - 3.34) | 0.154 | 01 | 15.2 | 12 | 17.57 ± 6.5 14.3 (12.32) | 0.735 |
| 21 - 25 | 03 | 1.08 ± 0.34 1 (0.78 - 1.46) | 20 | 1.43 ± 1.27 0.91 (0.41 - 4.3) | 0.898 | 03 | 18.53 ± 4.47 16.1 (16 - 24) | 20 | 21.67 ± 5.01 21.1 (15 - 34) | 0.319 |
| All | 30 | 0.36 ± 0.35 0.24 (0.01 - 1.46) | 63 | 1.2 ± 1.3 0.83 (0.01 - 8.28) | 0.001 | 26 | 16.04 ± 5.19 15.2 (9.4 - 33.8) | 61 | 17.7 ± 5.84 15.2 (8.8 - 34.10) | 0.213 |
Ai, autoimmune; non-Ai, non-autoimmune * p value by Mann-Whitney U test; # p value by Student t-test.
Level of FCP at onset of diabetes was independently influenced by both age and BMI. Their combined influence on the level of FCP was lesser in autoimmune diabetes: 26% (R2 0.268) when compared with 49% (R2 0.499) in non-autoimmune diabetes (P value < 0.05 for both). FCP was 0.29 nmol/l higher per 1 kg/m2 higher BMI in autoimmune and 0.66 nmol/l higher in NonAi, diabetes (P < 0.05 for NonAi). Mean FCP was correlated to increasing BMI, and BMI group, and to increasing age, also within each BMI group, and this was especially apparent in Ai diabetes.
Mean BMI for all was 17.2 ± 5.68 (range 8.8 - 34.1) kg/m2. Mean BMI for the Ab+ was 16.04 ± 5.19, which was lower than for the Ab− 17.7 ± 5.84 but there was no statistical significance (P = 0.213). This study did not show any change of BMI with antibody status H (2) = 1.9, P = 5.7 by Kruskal Wallis test (
ROC curves for the subjects are displayed in
The sensitivity and specificity of GADA at a cut-off of >20.75 nmol/l are 86.2% and 96.8% respectively is the most appropriate cut offs for diagnosing Ai in the region as the Youden’s Index is maximum at these levels. The values for that of C-peptide at a cut off of <0.36 nmol/l are 66.7% and 79.4% respectively, (Youden’s Index = 0.461) and seems to be the most appropriate cut offs for diagnosing Ai (
| C-peptide | |||||
|---|---|---|---|---|---|
| BMI Group | N | Autoimmune | N | Non-Autoimmune | P, Ai vs Non-Ai |
| Below normal | 10 | 0.38 ± 0.47 0.2 (0.01 - 1.46) | 22 | 0.67 ± 0.49 0.6 (0.06 - 1.89) | 0.05 |
| Normal | 14 | 0.36 ± 0.29 0.26 (0.01 - 0.93) | 32 | 1.02 ± 0.79 0.84 (0.01 - 0.48) | 0.001 |
| Above normal | 2 | 0.53 ± 0.47 0.53 (0.2 - 0.87) | 7 | 4.0 ± 1.9 4.04 (2.4 - 8.2) | 0.056 |
| All | 30 | 0.36 ± 0.35 0.24 (0.01 - 1.46) | 63 | 1.2 ± 1.3 0.83 (0.01 - 8.28) | <0.001 |
P value by Mann Whitney U test.
| Fasting C-Peptide (nmol/l) | Sensitivity (%) | Specificity (%) | YOUDEN’S INDEX |
|---|---|---|---|
| 0.250 | 0.500 | 0.873 | (Sn + Sp)−1 |
| 0.285 | 0.600 | 0.841 | 0.373 |
| 0.310 | 0.600 | 0.825 | 0.441 |
| 0.340 | 0.633 | 0.825 | 0.425 |
| 0.368 | 0.633 | 0.810 | 0.458 |
| 0.383 | 0.667 | 0.794 | 0.443 |
| GADA | |||
| 8.15 | 0.966 | 0.758 | 0.724 |
| 9.05 | 0.129 | 0.871 | 0 |
| 10.55 | 0.897 | 0.919 | 0.816 |
| 15.60 | 0.862 | 0.935 | 0.797 |
| 20.75 | 0.862 | 0.968 | 0.83 |
| 32.36 | 0.828 | 1.000 | 0.828 |
The difference in the mean years of presentation between autoimmune and no-autoimmune diabetes is almost 6 years indicating that the latter probably are Type 2 DM at a very early age of onset. Even though childhood-obesity has been claimed to be one of the important causes of early onset of Type 2 DM in paediatric population, our study did not reveal higher BMI (obesity) to be an important determinant for type of diabetes. It is at par with the observations that South East Asian and especially Indians have different presentations with regards to DM [
The current study did not show significant difference between the mean values of FBG, PPBG, and HbA1c but the C-peptide values were significantly lower in Ai group suggesting fairly preserved b-cell activity in them. Thus, in our population the type of DM in the Non-Ai group with higher prevalence of family history could be due to substantially early age at onset of Type 2 DM.
The current study showed the overall magnitude of autoantibody positivity of 32% which is much higher (58.1%) than previous studies conducted and reported in the Eastern part of India [
The differences in frequency of Ab+ between studies can be explained by the number and types of antibodies analyzed, duration of diabetes as well as ages in the populations studied. Patients testing negative for diabetes-associated autoantibodies at diagnosis seem to have a milder degree of beta-cell destruction. Interestingly, the higher FCP values in the age group of 21 - 25 years in the Ab+ group (
From the ROC analysis, our study demonstrates the utility of raised GADA (>20.75 nmol/l) as a very dependable test for diagnosing Ai in children and young adults. Its sensitivity and specificity are in the 86.2%, 96.8% and are the most appropriate cut offs for diagnosing Ai respectively. Low level of C-peptide (<0.36 nmol/l) is a fair indicator for diagnosing Ai diabetes in the same population. Hence C-peptide below 0.36 nmol/l may be taken as a screening tool for diagnosing Ai in the same population.
Raised ICA is a poor to fair indicator and BMI cannot be offered great credence as an indicator for diagnosing Ai Diabetes in children and young adults in our population. BMI was marginally lower in Ai+ than those negative for antibodies. As they cross the age of 20, behave more akin to Type 2 DM.
This study is one of the first of its kind to estimate dual autoimmune markers in children and young adults in the eastern part of India. This may pave the path for correct categorization of type of DM at the earliest and hence timely management and prevention of complications of DM in this community.
The current study revealed higher prevalence of anti-GAD ab (80%) positivity among Ai+ patients. Further, ROC analysis demonstrated the importance of raised values of anti-GAD ab (>20.75 nmol/l) as a very dependable parameter for diagnosing Ai in children and young adults. Its sensitivity and specificity were as high as 86.2% and 96.8% respectively. Even if ICA was positive in Ai group yet did not show much credence with regards to diagnosing Type 1 DM. Low level of C-peptide (<0.36 nmol/l) is a fair indicator for diagnosing Ai diabetes in the same population. However, BMI did not show any promise as an indicator for diagnosing the type of DM in children and young adults in our population. Studies with larger sample size may throw light on role of BMI and ICA in characterizing type of DM in children and young adults in India.
The authors declare no conflicts of interest regarding the publication of this paper.
Das, S., Routray, D., Behera, M. and Tripathy, S.K. (2022) Role of C-Peptide in Relation to Levels of Anti-GAD and Islet Cell Antibodies in Characterizing Types of Diabetes in the Young, in Eastern India. Journal of Diabetes Mellitus, 12, 1-11. https://doi.org/10.4236/jdm.2022.121001